EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOTSG00005027184
Gene Symbol: NTRK2
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOTSG00005041340
Gene Symbol: NTRK2
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOTSG00005044226
Gene Symbol: NTRK3
3 Cross references
198 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOTSG00005007479
Gene Symbol: NTRK1
1 Cross references
193 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOTSG00005016082
Gene Symbol: NTRK1
1 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOTSG00005046502
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOTSG00005008474
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOTSG00005041972
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSOTSG00005031685
Gene Symbol: NTRK3A
1 Cross references
198 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSOTSG00005045902
Gene Symbol: NFE2L2A
1 Cross references
199 Possible Orthologues:

Nicastrin

Ensembl ID : ENSOTSG00005015414
Gene Symbol: NCSTN
3 Cross references
197 Possible Orthologues:

Nicastrin

Ensembl ID : ENSOTSG00005034143
Gene Symbol: NCSTN
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).